SCHEMBL5238328

SCHEMBL5238328

CCOc1ccc2c(CC(=O)c3cccc(C)n3)ccnc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.44
TGFBR1 P36897 1/20 0.44
MAPK14 Q16539 1/20 0.44
SMN1; SMN2 Q16637 5/20 0.43
KDM4E B2RXH2 4/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 2/20 0.43
HSD17B10 Q99714 2/20 0.43
CYP1A2 P05177 1/20 0.43
TSHR P16473 1/20 0.43
NPC1 O15118 6/20 0.41
RAB9A P51151 6/20 0.41
MAPT P10636 4/20 0.41
PKM P14618 3/20 0.41
TP53 P04637 2/20 0.41
LMNA P02545 2/20 0.41
GBA1 P04062 1/20 0.41
GRM4 Q14833 1/20 0.39
OPRK1 P41145 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4873486 0.92 SMN1; SMN2 (0.47) THRBTGFBR1MAPK14SMN1; SMN2KDM4E
SCHEMBL5235795 0.90 KDR (0.45) TGFBR1ALDH1A1CYP1A2NPC1RAB9A
SCHEMBL5231287 0.85 NPC1 (0.49) SMN1; SMN2KDM4EALDH1A1HPGDNPC1
SCHEMBL4490632 0.83 P2RX7 (0.39) SMN1; SMN2KDM4EALDH1A1CYP1A2TSHR
SCHEMBL6671176 0.83 NPC1 (0.40) SMN1; SMN2ALDH1A1NPC1RAB9ATP53
SCHEMBL5231489 0.83 PRNP (0.45) THRBTGFBR1MAPK14SMN1; SMN2KDM4E
SCHEMBL23851296 0.82 MTNR1A (0.52) TGFBR1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL31461239 0.82 MTNR1A (0.52) TGFBR1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL5231308 0.81 SRC (0.42) TGFBR1AURKAMETKDRTEK
SCHEMBL29959459 0.81 CYP1A2 (0.49) TGFBR1MAPK14SMN1; SMN2ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1543001-B1 PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF CANCER LILLY CO ELI (US) 2007-08-15 EP disclosed
EP-1397364-B1 NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS LILLY CO ELI (US) 2007-07-25 EP disclosed
WO-2004026302-A1 METHODS OF INHIBITING TGF BETA WITH SUBSTITUTED PYRAZOLES ELI LILLY AND COMPANY (US) 2004-04-01 WO disclosed